ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

3:45PM-4:00PM: Abstract Number: 1707

Racial and Ethnic Disparities in Kidney Transplant Outcomes Among Patients With Systemic Lupus Erythematosus (SLE): A 20-Year Analysis Spanning Before and After the 2014 Kidney Allocation System Revision

Abstracts: Healthcare Disparities in Rheumatology (1704–1709)

3:45PM-4:00PM: Abstract Number: 1695

The B Cell Compartment Exhibits a Pro-Inflammatory Skewing During Progression to Rheumatoid Arthritis

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (1691–1697)

4:00PM-4:15PM: Abstract Number: 1696

A multi-omics resource of B cell activation reveals genetic mechanisms for autoimmune diseases

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (1691–1697)

4:00PM-4:15PM: Abstract Number: 1708

Assessing Social Determinants of Health Using PRAPARE in a Rheumatology Patient Navigator Program for Underserved Brooklyn Communities

Abstracts: Healthcare Disparities in Rheumatology (1704–1709)

4:00PM-4:15PM: Abstract Number: 1720

Comparison of Mortality Trends in Adults with Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A 21-Year Analysis Using CDC WONDER DATABASE.

Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes II: Morbidity & Mortality (1716–1721)

4:00PM-4:15PM: Abstract Number: 1690

Environmental Heat Exposure and Risk of Systemic Lupus Erythematosus

Abstracts: ARP I: Multidimensional Influences on Health in SLE (1686–1691)

4:00PM-4:15PM: Abstract Number: 1702

Powerful and Accurate Case-Control Analysis of Spatially Resolved Molecular Data in Autoimmune Disease

Abstracts: Genetics, Genomics & Proteomics (1698–1703)

4:00PM-4:15PM: Abstract Number: 1714

The perimenopause period is associated with increased levels of disease activity in psoriatic arthritis

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: Advances in Psoriatic Disease (1710–1715)

4:15PM-4:30PM: Abstract Number: 1709

Association Between Social Risk Factors and Major Adverse Cardiovascular Events Among Individuals with Rheumatic Conditions

Abstracts: Healthcare Disparities in Rheumatology (1704–1709)

4:15PM-4:30PM: Abstract Number: 1697

Dynamic Effects of T cell Engager Therapy on B and T cells in Autoimmune Disease.

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (1691–1697)

4:15PM-4:30PM: Abstract Number: 1721

Excess Mortality in SLE Is Concentrated in Lupus Nephritis and aPL-Positive Subsets: A population-based inception cohort study

Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes II: Morbidity & Mortality (1716–1721)

4:15PM-4:30PM: Abstract Number: 1703

Predicting Rheumatoid Arthritis Flare Using Longitudinal Cytokine Trajectories, Machine Learning and Spatial Transcriptomic Imaging

Abstracts: Genetics, Genomics & Proteomics (1698–1703)

4:15PM-4:30PM: Abstract Number: 1715

Spondyloarthritis and Psoriatic Arthritis Patients Under Immunosuppressive Conventional and Biologic DMARDs: Favorable Disease Safety and Attenuated Immunogenicity Following Recombinant Herpes Zoster Vaccination

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: Advances in Psoriatic Disease (1710–1715)

4:15PM-4:30PM: Abstract Number: 1691

Standardizing DXA Screening in Childhood-Onset Systemic Lupus Erythematosus at A Single Center: A Quality Improvement Initiative Using a Decision-Tree Algorithm

Abstracts: ARP I: Multidimensional Influences on Health in SLE (1686–1691)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].